By Kelly Cloonan
Korro Bio plans to cut about 20% of its workforce in an attempt to streamline operations and reach key program milestones.
The clinical-stage biopharmaceutical company said Wednesday the restructuring will incur one-time charges of around $1.2 million, including employee severance, benefits and other termination costs. It expects to recognize the majority of those charges in the second quarter.
Korro had 104 full-time employees as of Dec. 31, according to the company's most recent 10K filing.
The actions will help the company complete its Phase 1/2a Rewrite clinical trial in 2026, nominate a second development candidate and advance up to two programs under a collaboration with Novo Nordisk, Korro said.
The company will also continue to prioritize the development of KRRO-110 alongside investments in its Oligonucleotide Promoted Editing of RNA platform.
Based in Cambridge, Mass., Korro is focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 07, 2025 18:29 ET (22:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.